A clinical study on the efficacy of a novel herbal medicine cocktail in enhancing HIFU treatment for adenomyosis: a pilot randomized controlled trial.

Int J HyperthermiaSep 25, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Ting Lin, Minqi Su, Yan Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the efficacy of a Traditional Chinese Medicine (TCM) formula combined with High-Intensity Focused Ultrasound (HIFU) in 66 patients with adenomyosis. The study found that the observation group experienced significantly lower Visual Analog Scale (VAS) scores for pain and greater reductions in uterine and lesion volumes compared to the control group (p < 0.05).

Key findings

  • VAS scores were significantly lower in the observation group compared to the control group after treatment (p < 0.05).
  • The reduction in uterine and lesion volumes was greater in the observation group than in the control group (p < 0.05).
  • Serum levels of CA125 and IL-6 decreased more significantly in the observation group (p < 0.05).

Why it matters

The findings suggest that combining TCM with HIFU may enhance treatment outcomes for adenomyosis, particularly in pain management and lesion reduction. This could inform future treatment strategies in managing this condition.

Source

PubMed · PMID 42788264

Published in Int J Hyperthermia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.